OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in Boston
Melbourne, Australia, 05 June 2023: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, announced today that its Executive Chair, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis, will be attending the 2023 Biotechnology Innovation Organisation International Convention (BIO) from 5-8 June in Boston. OccuRx […]
Celebrate World Kidney Day and Show your Kidneys some love.
Melbourne, Australia, 9 March 2023: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Today kidney health awareness becomes a focus globally during World Kidney Day. The theme this year is Kidney Health for All – Preparing for the unexpected, supporting the vulnerable 2023 Campaign – World Kidney Day […]
OccuRx joins 41st Annual J.P. Morgan Healthcare Conference, San Francisco
Melbourne, Australia, 09 January 2023: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, are pleased to announce Executive Chair, Professor Darren Kelly, and Chief Commercial Officer Dr Gareth Lewis will be participating in the 41st Annual J.P. Morgan Healthcare Conference and associated partnering meetings from […]
OccuRx raises awareness of the importance of World Diabetes Day
Melbourne, Australia, 14 November 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, raises awareness of World Diabetes Day (WDD). WDD is the world’s largest diabetes awareness campaign reaching a global audience of over 1 billion people in more than 160 countries. The campaign draws […]
OccuRx team to meet with biotech industry leaders during AusBiotech conference in Perth, Australia
Melbourne, Australia, 20 October 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s AusBiotech Convention will be attended by OccuRx’s Chief Operating Officer, Dr Michelle Bradney. AusBiotech is scheduled to take place 26 – 28 October 2022 in Perth, Western Australia and will […]
OccuRx team to meet with biotech industry leaders during BIO-Europe® conference in Germany
Melbourne, Australia, 17 October 2022: OccuRx,a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s BIO-Europe Convention will be attended by OccuRx’s Chief Executive Officer, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis. BIO-Europe® is scheduled to take place 24 – 26 October 2022 […]
$16M cash injection to progress first-in-class therapy for inflammation and fibrosis – Start Up Daily
Melbourne, Australia, 09 September 2022 written by Simon Thomsen: Australian biotech start-up OccuRx today announces a $16m cash injection to progress into clinical phase studies for its oral therapy for inflammation and fibrosis – one of the leading causes of deaths globally[1]. This investment in OccuRx was jointly led by Brandon BioCatalyst and Uniseed and […]
OccuRx secures $1.5M to advance its Phase II Chronic Kidney Disease Study
Melbourne, Australia, 20 July 2022: OccuRx has been awarded a $1.5m grant from CUREator, Australia’s biomedical incubator managed by Brandon BioCatalyst. The funds will allow OccuRx to further investigate a novel therapy (OCX063) for treating inflammation and fibrosis in patients with chronic kidney disease (CKD). Chronic kidney disease (including diabetic kidney disease) is one of […]
OccuRx appoints Dr Gareth Lewis as Chief Commercial Officer
Melbourne, Australia, 20 June 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces Dr Gareth Lewis has been appointed as Chief Commercial Officer. Gareth has over 25 years of R&D experience spanning drug and clinical development, portfolio strategy, pre-launch commercialisation, business development and […]
OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in San Diego
Melbourne, Australia, 16 June 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces its senior team including Executive Chair, Prof Darren Kelly, will be attending the 2022 Biotechnology Innovation Organisation International Convention (“BIO”) held between 13-16 June 2022 in San Diego, California. OccuRx […]
